Table 3 Clinical safety outcomes
AutoKinetics (132) | Control (120) | p value | |
|---|---|---|---|
ICU mortality, n (%) | 45 (34.1) | 44 (36.7) | 0.768a |
Hospital mortality, n (%) | 45 (34.1) | 47 (39.2) | 0.481a |
28-day mortality, n (%) | 45 (34.1) | 48 (40.0) | 0.401a |
6-month mortality, n (%) | 56 (42.4) | 59 (49.2) | 0.344a |
New onset AKI, n (%) | 44 (33.3) | 50 (41.7) | 0.217a |
Highest KDIGO stage, n (%) | 0.081a | ||
0 | 30 (22.7) | 15 (12.5) | |
1 | 11 (8.3) | 19 (15.8) | |
2 | 47 (35.6) | 44 (36.7) | |
3 | 44 (33.3) | 42 (35.0) | |
Received CVVH, n (%) | 18 (13.6) | 19 (15.8) | 0.754 |
Days free from CVVH, mean (SD) | 10.0 (18.8) | 8.5 (11.4) | 0.856b |
SOFA score at 96 h, median (IQR) | 10.0 (6.0 to 15.2) | 10.0 (5.0 to 19.2) | 0.919b |
Delta SOFA score at 96 h, median (IQR) | 0.0 (− 3.0 to 4.0) | 0.0 (− 2.0 to 4.0) | 0.238b |
Hospital LOS, median (IQR) | 14.0 (4.6 to 30.2) | 12.2 (3.4 to 28.4) | 0.437b |
ICU LOS, median (IQR) | 3.8 (1.6 to 11.7) | 3.6 (1.0 to 11.0) | 0.594b |